| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H7N.2Cl.Pt.H3N |
| Molecular Weight | 376.147 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N.[Cl-].[Cl-].[Pt++].CC1=NC=CC=C1
InChI
InChIKey=IIMIOEBMYPRQGU-UHFFFAOYSA-L
InChI=1S/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2
Picoplatin is a sterically hindered platinum (II) complex with antineoplastic properties developed for the treatment of cis-platin-resistant cancer. Picoplatin alkylates DNA, forming both inter- and intra-strand cross-linkages, resulting in inhibition of DNA replication and transcription, and the induction of apoptosis. However, in Phase III trials, picoplatin failed to meet its primary endpoint for advanced cell lung cancer. It remains in development for other cancers.
Approval Year
Sourcing
Sample Use Guides
In a clinical trial, picoplatin was administered intravenously at a dose of 150 mg/m2 every 3 weeks.
Route of Administration:
Intravenous
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
